$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity 원문보기

Genome research, v.27 no.10, 2017년, pp.1645 - 1657  

Andrysik, Zdenek (Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, USA) ,  Galbraith, Matthew D. ,  Guarnieri, Anna L. (Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, USA) ,  Zaccara, Sara ,  Sullivan, Kelly D. (Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, USA) ,  Pandey, Ahwan ,  MacBeth, Morgan (Centre for Integrative Biology (CIBIO), University of Trento, 38123 Trento, TN, Italy) ,  Inga, Alberto ,  Espinosa, Joaquín M. (Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, USA)

Abstract AI-Helper 아이콘AI-Helper

The tumor suppressor TP53 is the most frequently mutated gene product in human cancer. Close to half of all solid tumors carry inactivating mutations in the TP53 gene, while in the remaining cases, TP53 activity is abrogated by other oncogenic events, such as hyperactivation of its endogenous repres...

참고문헌 (44)

  1. Adelman K , Kennedy MA , Nechaev S , Gilchrist DA , Muse GW , Chinenov Y , Rogatsky I . 2009 Immediate mediators of the inflammatory response are poised for gene activation through RNA polymerase II stalling . Proc Natl Acad Sci 106 : 18207 – 18212 . 19820169 

  2. Allen MA , Andrysik Z , Dengler VL , Mellert HS , Guarnieri A , Freeman JA , Sullivan KD , Galbraith MD , Luo X , Kraus WL , et al. 2014 Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms . eLife 3 : e02200 . 24867637 

  3. Brady CA , Jiang D , Mello SS , Johnson TM , Jarvis LA , Kozak MM , Kenzelmann Broz D , Basak S , Park EJ , McLaughlin ME , 2011 Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression . Cell 145 : 571 – 583 . 21565614 

  4. Brummelkamp TR , Fabius AW , Mullenders J , Madiredjo M , Velds A , Kerkhoven RM , Bernards R , Beijersbergen RL . 2006 An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors . Nat Chem Biol 2 : 202 – 206 . 16474381 

  5. el-Deiry WS , Tokino T , Velculescu VE , Levy DB , Parsons R , Trent JM , Lin D , Mercer WE , Kinzler KW , Vogelstein B . 1993 WAF1, a potential mediator of p53 tumor suppression . Cell 75 : 817 – 825 . 8242752 

  6. Fischer M . 2017 Census and evaluation of p53 target genes . Oncogene 36 : 3943 – 3956 . 28288132 

  7. Fischer M , Steiner L , Engeland K . 2014 The transcription factor p53: not a repressor, solely an activator . Cell Cycle 13 : 3037 – 3058 . 25486564 

  8. Freed-Pastor WA , Prives C . 2012 Mutant p53: one name, many proteins . Genes Dev 26 : 1268 – 1286 . 22713868 

  9. Galbraith MD , Allen MA , Bensard CL , Wang X , Schwinn MK , Qin B , Long HW , Daniels DL , Hahn WC , Dowell RD , 2013 HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia . Cell 153 : 1327 – 1339 . 23746844 

  10. Gomes NP , Bjerke G , Llorente B , Szostek SA , Emerson BM , Espinosa JM . 2006 Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program . Genes Dev 20 : 601 – 612 . 16510875 

  11. Guertin MJ , Lis JT . 2013 Mechanisms by which transcription factors gain access to target sequence elements in chromatin . Curr Opin Genet Dev 23 : 116 – 123 . 23266217 

  12. Hainaut P , Pfeifer GP . 2016 Somatic TP53 mutations in the era of genome sequencing . Cold Spring Harb Perspect Med 6 : a026179 . 27503997 

  13. Hemann MT , Zilfou JT , Zhao Z , Burgess DJ , Hannon GJ , Lowe SW . 2004 Suppression of tumorigenesis by the p53 target PUMA . Proc Natl Acad Sci 101 : 9333 – 9338 . 15192153 

  14. Henry RE , Andrysik Z , Paris R , Galbraith MD , Espinosa JM . 2012 A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX . EMBO J 31 : 1266 – 1278 . 22246181 

  15. Jiang L , Kon N , Li T , Wang SJ , Su T , Hibshoosh H , Baer R , Gu W . 2015 Ferroptosis as a p53-mediated activity during tumour suppression . Nature 520 : 57 – 62 . 25799988 

  16. Kenzelmann Broz D , Spano Mello S , Bieging KT , Jiang D , Dusek RL , Brady CA , Sidow A , Attardi LD . 2013 Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses . Genes Dev 27 : 1016 – 1031 . 23651856 

  17. Kubbutat MH , Jones SN , Vousden KH . 1997 Regulation of p53 stability by Mdm2 . Nature 387 : 299 – 303 . 9153396 

  18. Lawrence MS , Stojanov P , Polak P , Kryukov GV , Cibulskis K , Sivachenko A , Carter SL , Stewart C , Mermel CH , Roberts SA , 2013 Mutational heterogeneity in cancer and the search for new cancer-associated genes . Nature 499 : 214 – 218 . 23770567 

  19. Lawrence MS , Stojanov P , Mermel CH , Robinson JT , Garraway LA , Golub TR , Meyerson M , Gabriel SB , Lander ES , Getz G . 2014 Discovery and saturation analysis of cancer genes across 21 tumour types . Nature 505 : 495 – 501 . 24390350 

  20. Leach FS , Tokino T , Meltzer P , Burrell M , Oliner JD , Smith S , Hill DE , Sidransky D , Kinzler KW , Vogelstein B . 1993 p53 Mutation and MDM2 amplification in human soft tissue sarcomas . Cancer Res 53 : 2231 – 2234 . 8387391 

  21. Li M , He Y , Dubois W , Wu X , Shi J , Huang J . 2012a Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells . Mol Cell 46 : 30 – 42 . 22387025 

  22. Li T , Kon N , Jiang L , Tan M , Ludwig T , Zhao Y , Baer R , Gu W . 2012b Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence . Cell 149 : 1269 – 1283 . 22682249 

  23. Lin C , Garrett AS , De Kumar B , Smith ER , Gogol M , Seidel C , Krumlauf R , Shilatifard A . 2011 Dynamic transcriptional events in embryonic stem cells mediated by the super elongation complex (SEC) . Genes Dev 25 : 1486 – 1498 . 21764852 

  24. Menendez D , Nguyen TA , Freudenberg JM , Mathew VJ , Anderson CW , Jothi R , Resnick MA . 2013 Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells . Nucleic Acids Res 41 : 7286 – 7301 . 23775793 

  25. Mermel CH , Schumacher SE , Hill B , Meyerson ML , Beroukhim R , Getz G . 2011 GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers . Genome Biol 12 : R41 . 21527027 

  26. Nikulenkov F , Spinnler C , Li H , Tonelli C , Shi Y , Turunen M , Kivioja T , Ignatiev I , Kel A , Taipale J , 2012 Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis . Cell Death Differ 19 : 1992 – 2002 . 22790872 

  27. Riemenschneider MJ , Buschges R , Wolter M , Reifenberger J , Bostrom J , Kraus JA , Schlegel U , Reifenberger G . 1999 Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification . Cancer Res 59 : 6091 – 6096 . 10626796 

  28. Schlereth K , Heyl C , Krampitz AM , Mernberger M , Finkernagel F , Scharfe M , Jarek M , Leich E , Rosenwald A , Stiewe T . 2013 Characterization of the p53 cistrome—DNA binding cooperativity dissects p53's tumor suppressor functions . PLoS Genet 9 : e1003726 . 23966881 

  29. Soussi T , Kato S , Levy PP , Ishioka C . 2005 Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations . Hum Mutat 25 : 6 – 17 . 15580553 

  30. Sullivan KD , Padilla-Just N , Henry RE , Porter CC , Kim J , Tentler JJ , Eckhardt SG , Tan AC , DeGregori J , Espinosa JM . 2012 ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53 . Nat Chem Biol 8 : 646 – 654 . 22660439 

  31. Takagi M , Absalon MJ , McLure KG , Kastan MB . 2005 Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin . Cell 123 : 49 – 63 . 16213212 

  32. Timofeev O , Schlereth K , Wanzel M , Braun A , Nieswandt B , Pagenstecher A , Rosenwald A , Elsasser HP , Stiewe T . 2013 p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo . Cell Rep 3 : 1512 – 1525 . 23665223 

  33. Tonelli C , Morelli MJ , Sabo A , Verrecchia A , Rotta L , Capra T , Bianchi S , Campaner S , Amati B . 2017 Genome-wide analysis of p53-regulated transcription in Myc-driven lymphomas . Oncogene 36 : 2921 – 2929 . 28092679 

  34. Tovar C , Rosinski J , Filipovic Z , Higgins B , Kolinsky K , Hilton H , Zhao X , Vu BT , Qing W , Packman K , 2006 Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy . Proc Natl Acad Sci 103 : 1888 – 1893 . 16443686 

  35. Valente LJ , Gray DH , Michalak EM , Pinon-Hofbauer J , Egle A , Scott CL , Janic A , Strasser A . 2013 p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa . Cell Rep 3 : 1339 – 1345 . 23665218 

  36. Vassilev LT , Vu BT , Graves B , Carvajal D , Podlaski F , Filipovic Z , Kong N , Kammlott U , Lukacs C , Klein C , 2004 In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 . Science 303 : 844 – 848 . 14704432 

  37. Verfaillie A , Svetlichnyy D , Imrichova H , Davie K , Fiers M , Kalender Atak Z , Hulselmans G , Christiaens V , Aerts S . 2016 Multiplex enhancer-reporter assays uncover unsophisticated TP53 enhancer logic . Genome Res 26 : 882 – 895 . 27197205 

  38. Vousden KH , Prives C . 2009 Blinded by the light: the growing complexity of p53 . Cell 137 : 413 – 431 . 19410540 

  39. Vousden KH , Ryan KM . 2009 p53 and metabolism . Nat Rev Cancer 9 : 691 – 700 . 19759539 

  40. Wagner A . 2005 Distributed robustness versus redundancy as causes of mutational robustness . Bioessays 27 : 176 – 188 . 15666345 

  41. Wang D , Garcia-Bassets I , Benner C , Li W , Su X , Zhou Y , Qiu J , Liu W , Kaikkonen MU , Ohgi KA , 2011 Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA . Nature 474 : 390 – 394 . 21572438 

  42. Wang B , Niu D , Lam TH , Xiao Z , Ren EC . 2014 Mapping the p53 transcriptome universe using p53 natural polymorphs . Cell Death Differ 21 : 521 – 532 . 24076587 

  43. Wei CL , Wu Q , Vega VB , Chiu KP , Ng P , Zhang T , Shahab A , Yong HC , Fu Y , Weng Z , 2006 A global map of p53 transcription-factor binding sites in the human genome . Cell 124 : 207 – 219 . 16413492 

  44. Zaccara S , Tebaldi T , Pederiva C , Ciribilli Y , Bisio A , Inga A . 2014 p53-directed translational control can shape and expand the universe of p53 target genes . Cell Death Differ 21 : 1522 – 1534 . 24926617 

관련 콘텐츠

오픈액세스(OA) 유형

GOLD(Hybrid)

저자가 APC(Article Processing Charge)를 지불한 논문에 한하여 자유로운 이용이 가능한, hybrid 저널에 출판된 논문

이 논문과 함께 이용한 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로